Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

AXL is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, De Marzo AM, Pienta KJ.

Mol Cancer Res. 2018 Oct 5. pii: molcanres.0718.2018. doi: 10.1158/1541-7786.MCR-18-0718. [Epub ahead of print]

PMID:
30291220
2.

Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.

Salas Fragomeni RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2018 Nov;43(11):e419-e421. doi: 10.1097/RLU.0000000000002280.

PMID:
30247210
3.

3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wett JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Sep 12;8(1):13658. doi: 10.1038/s41598-018-31924-2.

4.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2477-2. [Epub ahead of print]

PMID:
30191396
5.

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

J Nucl Med. 2018 Sep 6. pii: jnumed.118.217588. doi: 10.2967/jnumed.118.217588. [Epub ahead of print]

PMID:
30190304
6.

Follow-Up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

J Nucl Med. 2018 Sep 6. pii: jnumed.118.217653. doi: 10.2967/jnumed.118.217653. [Epub ahead of print]

PMID:
30190303
7.

O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.

Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya MA, Wang X, Simons BW, Ballew M, Nugent K, Groves J, Williams RD, Shiraishi T, Verdone J, Yildirir G, Henry R, Zhang B, Wong J, Wang KK, Nelkin BD, Pienta KJ, Felsher D, Zachara NE, Tran PT.

J Clin Invest. 2018 Aug 21. pii: 94844. doi: 10.1172/JCI94844. [Epub ahead of print]

8.

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

Ann Nucl Med. 2018 Oct;32(8):512-522. doi: 10.1007/s12149-018-1291-7. Epub 2018 Aug 14. Review.

PMID:
30109562
9.

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays-Reply.

Torga G, Pienta KJ.

JAMA Oncol. 2018 Oct 1;4(10):1431-1432. doi: 10.1001/jamaoncol.2018.2326. No abstract available.

PMID:
30027215
10.

Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells.

Axelrod HD, Pienta KJ, Valkenburg KC.

Biol Proced Online. 2018 Jul 1;20:13. doi: 10.1186/s12575-018-0078-5. eCollection 2018.

11.

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.

Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE.

Prostate Cancer Prostatic Dis. 2018 Jul 9. doi: 10.1038/s41391-018-0061-x. [Epub ahead of print]

PMID:
29988102
12.

Cancer as a Social Dysfunction-Why Cancer Research Needs New Thinking.

Axelrod R, Pienta KJ.

Mol Cancer Res. 2018 Sep;16(9):1346-1347. doi: 10.1158/1541-7786.MCR-18-0013. Epub 2018 May 21.

PMID:
29784670
13.

Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages.

de Groot AE, Pienta KJ.

Oncotarget. 2018 Feb 21;9(29):20908-20927. doi: 10.18632/oncotarget.24556. eCollection 2018 Apr 17. Review.

14.

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.

Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1. Review.

PMID:
29717499
15.

Ten unanswered questions in cancer: "If this is true, what does it imply"?

Amend SR, de Groot AE, Torga G, Axelrod HD, Reyes DK, Valkenburg KC, Glavaris SA, Pienta KJ.

Am J Clin Exp Urol. 2018 Apr 1;6(2):26-31. eCollection 2018. No abstract available.

16.

Targeting the tumour stroma to improve cancer therapy.

Valkenburg KC, de Groot AE, Pienta KJ.

Nat Rev Clin Oncol. 2018 Jun;15(6):366-381. doi: 10.1038/s41571-018-0007-1. Review.

PMID:
29651130
17.

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18F-DCFPyL Positron Emission Tomography Imaging.

Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP, Pienta KJ.

Urology. 2018 Jul;117:18-21. doi: 10.1016/j.urology.2018.03.030. Epub 2018 Apr 4. No abstract available.

18.

SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.

Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C.

J Nucl Med. 2018 Jul;59(7):1085-1091. doi: 10.2967/jnumed.117.206631. Epub 2018 Mar 23.

PMID:
29572257
19.

Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem.

Frost JJ, Pienta KJ, Coffey DS.

Oncotarget. 2017 Dec 5;9(14):11429-11440. doi: 10.18632/oncotarget.22939. eCollection 2018 Feb 20.

20.

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation.

Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP.

Urol Case Rep. 2017 Dec 19;17:22-25. doi: 10.1016/j.eucr.2017.12.011. eCollection 2018 Mar.

21.

Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape.

Lin KC, Torga G, Wu A, Rabinowitz JD, Murray WJ, Sturm JC, Pienta KJ, Austin R.

Converg Sci Phys Oncol. 2017 Dec;3(4). pii: 045001. Epub 2017 Aug 30.

22.

PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.

Carleton NM, Zhu G, Gorbounov M, Miller MC, Pienta KJ, Resar LMS, Veltri RW.

Prostate. 2018 May;78(7):547-559. doi: 10.1002/pros.23499. Epub 2018 Mar 9.

PMID:
29520928
23.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.

PMID:
29432873
24.

CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, Lee E, Wang Y, Chung JS, Gursky AM, Krebsbach PH, Pienta KJ, Morgan TM, Taichman RS.

Cancer Res. 2018 Apr 15;78(8):2026-2039. doi: 10.1158/0008-5472.CAN-17-2332. Epub 2018 Feb 5.

PMID:
29431639
25.

Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis.

Hill EE, Kim JK, Jung Y, Neeley CK, Pienta KJ, Taichman RS, Nor JE, Baker JR Jr, Krebsbach PH.

J Cell Biochem. 2018 Nov;119(10):8074-8083. doi: 10.1002/jcb.26727. Epub 2018 Jun 22.

PMID:
29380900
26.

Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.

Chalfin HJ, Glavaris SA, Malihi PD, Sperger JM, Gorin MA, Lu C, Goodwin CR, Chen Y, Caruso EA, Dumpit R, Kuhn P, Lang JM, Nelson PS, Luo J, Pienta KJ.

J Urol. 2018 Jun;199(6):1494-1501. doi: 10.1016/j.juro.2018.01.033. Epub 2018 Jan 12.

PMID:
29339080
27.

Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.

Barakat DJ, Suresh R, Barberi T, Pienta KJ, Simons BW, Friedman AD.

PLoS One. 2018 Jan 11;13(1):e0191188. doi: 10.1371/journal.pone.0191188. eCollection 2018.

28.

Analogous detection of circulating tumor cells using the AccuCyte® -CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer.

van der Toom EE, Groot VP, Glavaris SA, Gemenetzis G, Chalfin HJ, Wood LD, Wolfgang CL, de la Rosette JJMCH, de Reijke TM, Pienta KJ.

Prostate. 2018 Mar;78(4):300-307. doi: 10.1002/pros.23474. Epub 2017 Dec 29.

PMID:
29285777
29.

Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests.

Torga G, Pienta KJ.

JAMA Oncol. 2018 Jun 1;4(6):868-870. doi: 10.1001/jamaoncol.2017.4027. No abstract available.

PMID:
29242909
30.

Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype.

Li F, Glinskii OV, Mooney BP, Rittenhouse-Olson K, Pienta KJ, Glinsky VV.

Oncotarget. 2017 Oct 20;8(58):98598-98608. doi: 10.18632/oncotarget.21985. eCollection 2017 Nov 17.

31.

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT.

Phillips RM, Gorin MA, Rowe SP, Pomper MG, Pienta KJ, Ross AE, Tran PT.

Urol Case Rep. 2017 Nov 22;16:86-88. doi: 10.1016/j.eucr.2017.11.021. eCollection 2018 Jan. No abstract available.

32.

Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Dong L, Pienta KJ.

Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31023-0. doi: 10.1016/j.eururo.2017.11.031. [Epub ahead of print] No abstract available.

PMID:
29221660
33.

Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.

Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, Wilkinson JE, Wang Y, Daignault-Newton S, Pienta KJ, Morgan TM, Keller ET, Nör JE, Shea LD, McCauley LK.

J Clin Invest. 2018 Jan 2;128(1):248-266. doi: 10.1172/JCI92466. Epub 2017 Nov 27.

34.

PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.

Rowe SP, Pienta KJ, Pomper MG, Gorin MA.

Eur Urol. 2018 Apr;73(4):485-487. doi: 10.1016/j.eururo.2017.10.027. Epub 2017 Nov 11.

PMID:
29132714
35.

Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.

Chalfin HJ, Pienta KJ, Gorin MA.

BJU Int. 2017 Nov;120(5B):E4. doi: 10.1111/bju.13720. No abstract available.

PMID:
29105994
36.

Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.

Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold S, Pienta KJ, Pomper MG.

J Nucl Med. 2018 Mar;59(3):486-493. doi: 10.2967/jnumed.117.191221. Epub 2017 Oct 12.

37.

Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Nov;77(15):1478-1488. doi: 10.1002/pros.23424. Epub 2017 Sep 18. Review.

PMID:
28925066
38.

Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.

San Martin R, Pathak R, Jain A, Jung SY, Hilsenbeck SG, Piña-Barba MC, Sikora AG, Pienta KJ, Rowley DR.

Cancer Res. 2017 Nov 1;77(21):5977-5988. doi: 10.1158/0008-5472.CAN-17-0064. Epub 2017 Sep 15.

PMID:
28916657
39.

Classifying the evolutionary and ecological features of neoplasms.

Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D.

Nat Rev Cancer. 2017 Oct;17(10):605-619. doi: 10.1038/nrc.2017.69. Epub 2017 Sep 15. Review.

40.

Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Rowe SP, Pienta KJ, Pomper MG, Gorin MA.

J Nucl Med. 2018 Mar;59(3):479-485. doi: 10.2967/jnumed.117.195255. Epub 2017 Sep 8. No abstract available.

PMID:
28887401
41.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
42.

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia.

Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, Allaf ME, Pienta KJ, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP.

Ann Nucl Med. 2017 Nov;31(9):696-702. doi: 10.1007/s12149-017-1201-4. Epub 2017 Aug 22.

43.

An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT.

Rowe SP, Gorin MA, Chu LC, Pienta KJ, Pomper MG, Ross AE, Macura KJ.

Clin Nucl Med. 2017 Oct;42(10):e441-e443. doi: 10.1097/RLU.0000000000001785.

PMID:
28806262
44.

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136. doi: 10.1007/s00259-017-3780-7. Epub 2017 Aug 1. Review.

PMID:
28765998
45.

Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME.

J Urol. 2018 Jan;199(1):126-132. doi: 10.1016/j.juro.2017.07.070. Epub 2017 Jul 20.

46.

Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.

Gorin MA, Pomper MG, Pienta KJ, Rowe SP.

BJU Int. 2017 Aug;120(2):160-161. doi: 10.1111/bju.13801. No abstract available.

47.

Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.

Gorin MA, Marashdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP.

Nucl Med Commun. 2017 Sep;38(9):795-798. doi: 10.1097/MNM.0000000000000716.

PMID:
28704341
48.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

49.

Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.

Parsana P, Amend SR, Hernandez J, Pienta KJ, Battle A.

BMC Cancer. 2017 Jun 26;17(1):447. doi: 10.1186/s12885-017-3413-3.

50.

Prostate Cancer Local Recurrence Detected With Both 18F-Fluciclovine and PSMA-targeted 18F-DCFPyL PET/CT.

Gorin MA, Pienta KJ, Pomper MG, Rowe SP.

Urology. 2017 Sep;107:e9-e10. doi: 10.1016/j.urology.2017.06.015. Epub 2017 Jun 19.

PMID:
28641974

Supplemental Content

Loading ...
Support Center